Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-05

Edgewise Therapeutics (EWTX)

CEO Kevin Koch was paid $7,359,546 in fiscal year 2025, ↓ down 3.2% from fiscal year 2024, the 47th percentile of its disclosed peer group (SEC filing 0001104659-26-047688 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,359,546 ↓
Kevin Koch total, FY2025
47th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
96.14%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Kevin Koch (President and Chief Executive Officer), FY2025 total compensation $7,359,546 (base salary $670,000) [exec_comp, SEC accession 0001104659-26-047688, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

EWTX's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Kevin Koch$670,000—$1,171,625$5,041,621$462,300—$14,000$7,359,546
President and Chief Executive Officer
Robert Blaustein525,000—999,4752,801,305227,605—14,0004,567,385
Former Chief Development Officer
Michael Nofi67,813—799,7503,387,20929,887—04,284,659
Chief Financial Officer
Behrad Derakhshan520,000—401,7001,728,428269,100—14,0002,933,228
Chief Operating Officer
Joanne Donovan530,358—376,5941,620,389243,965—14,0002,785,306
Chief Medical Officer
Alan Russell499,580—376,5941,620,389229,807—8,4792,734,849
Co-Founder and Chief Scientific Officer
R. Michael Carruthers465,694—392,7071,500,845214,219—14,0002,587,465
Former Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Kevin Koch$7,359,546$7,601,200$3,975,855↓ −241,654
Robert Blaustein4,567,385———
Michael Nofi4,284,659———
Behrad Derakhshan2,933,2282,896,1931,756,317↑ +37,035
Joanne Donovan2,785,3062,924,4741,716,844↓ −139,168
Alan Russell2,734,849———
R. Michael Carruthers2,587,465———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Edgewise Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper EWTX reports.

We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against EWTX
4 companies name EWTX as a compensation peer

Each company listed discloses EWTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EWTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Alan RussellExecutive$2,734,849
Behrad DerakhshanCOO$2,933,228
R. Michael CarruthersCFO$2,587,465
Kevin KochCEO$7,359,546
Robert BlausteinChief Development Officer$4,567,385
Michael NofiCFO$4,284,659
Joanne DonovanChief Medical Officer$2,785,306
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Arlene M. MorrisIndependent Director$361,977
Badreddin Edris, Ph.DIndependent Director$359,477
Christopher MartinIndependent Director$704,712
Jonathan C. Fox, M.D., Ph.DIndependent Director$349,477
Jonathan Root, M.DIndependent Director$359,477
Laura BregeIndependent Director$371,977
Peter Thompson, M.DDirector$384,477
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Joanne DonovanRSU17,344—$430,391
Behrad DerakhshanOption165,00013.39—
Kevin KochRSU87,500—2,171,313
Kevin KochRSU53,907—1,337,702
Michael NofiRSU43,750—1,085,656
Robert BlausteinRSU30,000—744,450
Behrad DerakhshanRSU30,000—744,450
Joanne DonovanRSU28,125—697,922
Alan RussellRSU28,125—697,922
R. Michael CarruthersRSU26,875—666,903
Behrad DerakhshanOption91,6677.08—
Robert BlausteinRSU17,500—434,263
R. Michael CarruthersRSU17,344—430,391
Behrad DerakhshanRSU17,344—430,391
Alan RussellRSU17,344—430,391
Kevin KochRSU41,545—0
Kevin KochRSU178,711—0
Kevin KochOption91,66710.39—
Kevin KochOption250,0007.08—
Kevin KochOption287,50017.05—
Kevin KochOption481,25013.39—
Michael NofiOption262,50018.28—
Robert BlausteinOption160,00027.39—
Robert BlausteinOption96,25013.39—
R. Michael CarruthersOption33,33410.39—
R. Michael CarruthersOption83,3347.08—
R. Michael CarruthersOption92,50017.05—
Behrad DerakhshanOption92,50017.05—
R. Michael CarruthersOption147,81313.39—
Behrad DerakhshanOption33,33410.39—
Joanne DonovanOption40,00010.39—
Joanne DonovanOption83,3347.08—
Joanne DonovanOption92,50017.05—
Joanne DonovanOption154,68813.39—
Alan RussellRSU1,147,365—0
Alan RussellRSU130,352—0
Alan RussellOption36,66710.39—
Alan RussellOption83,3347.08—
Alan RussellOption92,50017.05—
Alan RussellOption154,68813.39—
05

Incentive-plan design — the Compensation Discussion & Analysis

The compensation committee uses equity awards to deliver long-term incentive compensation opportunities to our named executive officers. These equity awards vest or may be earned over multi-year periods, which better serves our long-term value creation goals and retention objectives.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAlpine
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0487,055,1113,491,326577,25796.14%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0496.14%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Christopher MartinIndependent · Nominating & Corporate Governance$4,712—$700,000——$704,712
Peter Thompson, M.DNot independent80,000—304,477——384,477
Laura BregeIndependent · Audit (Chair) · Compensation67,500—304,477——371,977
Arlene M. MorrisIndependent · Audit · Compensation57,500—304,477——361,977
Badreddin Edris, Ph.DIndependent · Compensation (Chair)55,000—304,477——359,477
Jonathan Root, M.DIndependent · Audit · Nominating & Corporate Governance (Chair)55,000—304,477——359,477
Jonathan C. Fox, M.D., Ph.DIndependent · Audit45,000—304,477——349,477
Kevin Koch, Ph.DEmployee director—————0
Alan Russell, Ph.DEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$350,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$364,712
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$364,712

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Edgewise Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Edgewise Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Cogent Biosciences2025Andrew Robbins$724,554$12,993,250$13,447,680$561,600$27,762,684
2Avidity Biosciences2024Sarah Boyce659,90010,748,4802,157,090594,00014,176,480
3Janux Therapeutics2025David Campbell680,000012,459,031367,20013,506,231
4Protagonist Therapeutics2025Dinesh Patel715,5005,839,2045,618,010686,88012,871,506
5Enliven Therapeutics2025Richard Fair38,077011,880,138011,918,926
6Arcus Biosciences2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
7IDEAYA Biosciences2025Yujiro Hata700,00008,418,840378,0009,512,640
8Kymera Therapeutics2025Nello Mainolfi693,00007,318,859519,7508,545,609
9Edgewise Therapeutics2025Kevin Koch670,0001,171,6255,041,621462,3007,359,546
10Beam Therapeutics2025John Evans755,0001,513,5752,876,754662,5135,818,525
11Pliant Therapeutics2025Bernard Coulie682,0001,810,2502,713,750204,6005,462,901
12Denali Therapeutics2025Ryan Watts718,0001,151,8672,180,00304,751,515
13Rocket Pharmaceuticals2025Gaurav Shah671,076806,7511,613,377403,0483,510,241
14Keros Therapeutics2025Jasbir Seehra700,0001,426,2800398,1252,540,204
15Dyne Therapeutics2025John Cox721,0000937,893410,9702,076,868
16Zentalis Pharmaceuticals2025Julie Eastland700,00099,77256,975441,0001,300,731
—Aerovate Therapeutics——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Edgewise Therapeuticsnot disclosednot disclosednot disclosedAlpine
Aerovate Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Arcus Biosciences100%Options 67 · RSU 33not disclosedRadford
Avidity Biosciencesnot disclosedOption 80 · RSU 20not disclosedAlpine
Beam Therapeutics135%Options 66 · RSU 34not disclosedPay Governance LLC
Cogent Biosciences135%not disclosedNoCompensia
Denali Therapeutics145%not disclosednot disclosedAlpine Rewards
Dyne Therapeutics95%not disclosednot disclosedAlpine Rewards, LLC
Enliven Therapeuticsnot disclosedOption 100not disclosednot disclosed
IDEAYA Biosciences90%Options 100not disclosedAon (Aon plc, Talent Solutions practice)
Janux Therapeutics90%not disclosednot disclosedFW Cook
Keros Therapeutics87.5%RSU 50 · PSU 50NoAon (Human Capital Solutions practice)
Kymera Therapeutics125%not disclosedNoAlpine Rewards
Pliant Therapeuticsnot disclosedOption 66.67 · RSU 33.33not disclosedPearl Meyer; Alpine Rewards
Protagonist Therapeutics160%Options 50 · RSU 50not disclosedAon Human Capital Solutions
Rocket Pharmaceuticalsnot disclosednot disclosednot disclosedSemler Brossy
Zentalis Pharmaceuticals105%not disclosednot disclosedAnderson Pay Advisors LLC / Pay Governance LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Edgewise Therapeutics in fiscal 2025?
As disclosed, Kevin Koch (President and Chief Executive Officer) was the highest-paid executive at Edgewise Therapeutics in fiscal 2025, with total compensation of $7,359,546.
How does Edgewise Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Kevin Koch's total compensation ranked at the 47th percentile of Edgewise Therapeutics's disclosed peer group.
How did shareholders vote on Edgewise Therapeutics's executive compensation?
As disclosed, 96.14% of shareholders supported Edgewise Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Edgewise Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Edgewise Therapeutics reported total board compensation of $364,712 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Kevin KochDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 7,359,546. View filing ↗
2Section 01, Robert BlausteinDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 4,567,385. View filing ↗
3Section 01, Michael NofiDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 4,284,659. View filing ↗
4Section 01, Behrad DerakhshanDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 2,933,228. View filing ↗
5Section 01, Joanne DonovanDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 2,785,306. View filing ↗
6Section 01, Alan RussellDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 2,734,849. View filing ↗
7Section 01, R. Michael CarruthersDEF 14A2026-04-230001104659-26-047688Section “Executive Compensation”. As printed: 2,587,465. View filing ↗
8Section 08, Christopher MartinDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 704,712. View filing ↗
9Section 08, Peter Thompson, M.DDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 384,477. View filing ↗
10Section 08, Laura BregeDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 371,977. View filing ↗
11Section 08, Arlene M. MorrisDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 361,977. View filing ↗
12Section 08, Badreddin Edris, Ph.DDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 359,477. View filing ↗
13Section 08, Jonathan Root, M.DDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 359,477. View filing ↗
14Section 08, Jonathan C. Fox, M.D., Ph.DDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 349,477. View filing ↗
15Section 08, Kevin Koch, Ph.DDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 0. View filing ↗
16Section 08, Alan Russell, Ph.DDEF 14A2026-04-230001104659-26-047688Section “Director Compensation”. As printed: 0. View filing ↗
17Section 06, 2026 voteForm 8-K2026-06-050001104659-26-071011Item 5.07 · say-on-pay result. As reported: 96.14% (votes for as printed: 87,055,111). View filing ↗
18Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.
19Section 09b board cost (computed)Computed——Cash 364,712 + equity 0 + all other 0 = 364,712, summed across the director compensation table rows.
20Cogent Biosciences, Section 10b CEO totalDEF 14A2026-04-230001193125-26-173834CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
21Avidity Biosciences, Section 10b CEO totalDEF 14A2025-04-290001599901-25-000092CEO total compensation as printed in Avidity Biosciences's own proxy. As printed: 14,176,480. View filing ↗
22Janux Therapeutics, Section 10b CEO totalDEF 14A2026-04-280001193125-26-187095CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. View filing ↗
23Protagonist Therapeutics, Section 10b CEO totalDEF 14A2026-04-280001104659-26-050429CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. View filing ↗
24Enliven Therapeutics, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182045CEO total compensation as printed in Enliven Therapeutics's own proxy. As printed: 11,918,926. View filing ↗
25Arcus Biosciences, Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
26IDEAYA Biosciences, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191501CEO total compensation as printed in IDEAYA Biosciences's own proxy. As printed: 9,512,640. View filing ↗
27Kymera Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191495CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. View filing ↗
28Edgewise Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-230001104659-26-047688CEO total compensation as printed in Edgewise Therapeutics's own proxy. As printed: 7,359,546. View filing ↗
29Beam Therapeutics, Section 10b CEO totalDEF 14A2026-04-170001193125-26-161512CEO total compensation as printed in Beam Therapeutics's own proxy. As printed: 5,818,525. View filing ↗
30Pliant Therapeutics, Section 10b CEO totalDEF 14A2026-04-220001746473-26-000076CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. View filing ↗
31Denali Therapeutics, Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
32Rocket Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-060001140361-26-013335CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. View filing ↗
33Keros Therapeutics, Section 10b CEO totalDEF 14A2026-04-220001104659-26-046791CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. View filing ↗
34Dyne Therapeutics, Section 10b CEO totalDEF 14A2026-04-230001193125-26-173655CEO total compensation as printed in Dyne Therapeutics's own proxy. As printed: 2,076,868. View filing ↗
35Zentalis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-300001725160-26-000027CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. View filing ↗
36Section 10a, Zentalis Pharmaceuticals reciprocityDEF 14A—0001725160-24-000096Zentalis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
37Section 10a, Protagonist Therapeutics reciprocityDEF 14A—0001104659-26-050429Protagonist Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
38Section 10a, Keros Therapeutics reciprocityDEF 14A—0001104659-26-046791Keros Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
39Section 10a, Janux Therapeutics reciprocityDEF 14A—0001193125-26-187095Janux Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
40Section 10a, Pliant Therapeutics reciprocityDEF 14A—0001746473-26-000076Pliant Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
41Section 10a, Rocket Pharmaceuticals reciprocityDEF 14A—0001140361-25-016656Rocket Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
42Section 10a, Dyne Therapeutics reciprocityDEF 14A—0001193125-26-173655Dyne Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
43Section 10a, Denali Therapeutics reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
44Section 10a, Avidity Biosciences reciprocityDEF 14A—0001599901-25-000092Avidity Biosciences's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
45Section 10a, Beam Therapeutics reciprocityDEF 14A—0001193125-26-161512Beam Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
46Section 10a, Cogent Biosciences reciprocityDEF 14A—0001193125-26-173834Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
47Section 10a, IDEAYA Biosciences reciprocityDEF 14A—0001193125-26-191501IDEAYA Biosciences's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗
48Section 10a, Kymera Therapeutics reciprocityDEF 14A—0001193125-26-191495Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include Edgewise Therapeutics. View filing ↗